Pharmicell
Abschluss
Cashflow
Pharmicell (005690.KO) im Zahlenüberblick: Gewinn- und Verlustrechnung, Bilanz und Cashflow, wahlweise je Jahr oder Quartal. Im jüngsten Berichtszeitraum (Q1 26) lag „Operativer Cashflow" bei -1.461 Millionen KRW. Zeilen lassen sich per Häkchen als Diagramm vergleichen.
Alle Werte in Millionen KRW.
Zeilen ankreuzen und als Diagramm vergleichen (bis zu 4)
| Position | Q1 13 | Q2 13 | Q3 13 | Q4 13 | Q1 14 | Q2 14 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | -1.496 | -910 | -810 | -4.332 | -757 | 245 | -430 | 866 | 2.233 | 3.534 | 3.162 | 48 | -690 | 3.155 | 3.618 | -11.305 | 4.670 | -278 | 3.356 | 167 | 2.941 | 4.792 | 1.878 | 2.203 | -44 | -2.442 | 5.889 | 95 | -1.035 | 16.036 | 8.784 | 17.270 | -1.461 | 40.629 | |
| – | – | 813 | 998 | 886 | 409 | 405 | 495 | 316 | 576 | 445 | 433 | 444 | 447 | 436 | 334 | 403 | 563 | 647 | 214 | 611 | 714 | 700 | 708 | 708 | 725 | 739 | 741 | 791 | 792 | 767 | 765 | 745 | 757 | 789 | 3.056 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 17 | 276 | 278 | 278 | 184 | 1.017 | |
| – | – | -1.381 | 19.646 | 690 | 665 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | 684 | -1.267 | 1.481 | -1.750 | -2.910 | -842 | -752 | -11.938 | -1.133 | -3.203 | -762 | -402 | 1.253 | 1.916 | 49 | 173 | 512 | -6.238 | 3.867 | -5.674 | -10.499 | 7.450 | -1.380 | 4.331 | -16.372 | -5.970 | |
| 45 | 257 | 24 | 197 | 37 | 14 | 639 | 116 | 634 | 274 | 239 | 191 | 210 | 102 | 870 | 1.573 | 736 | 1.141 | 2.876 | 4.534 | 11.013 | 535 | 517 | 960 | 1.239 | 3.300 | 3.463 | 214 | 467 | 194 | 92 | 284 | 622 | 6.493 | 1.279 | 8.679 | |
| – | – | 3.864 | 5.605 | -117 | 1.159 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0,0 | 0,0 | – | – | |
| – | – | 5.000 | 5.000 | 2.000 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | 84 | -16.200 | 2.505 | 4.690 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0,0 | 0,0 | – | – | 0,0 | 6.000 | 5.942 | – | |
| – | – | 84 | -11.200 | 4.505 | 4.690 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | 2.452 | -6.505 | 3.579 | 1.518 | -1.352 | -66 | -1.014 | 548 | 2.029 | -716 | 2.868 | 54 | -965 | 15.343 | 3.566 | -12.670 | 2.004 | -7.207 | -6.975 | 325 | 3.517 | 5.536 | -4.735 | -4.953 | -3.231 | -5.461 | 5.070 | -1.841 | -1.266 | 21.982 | -9.750 | 9.625 | -5.970 | 15.887 | |
| – | – | – | – | – | – | – | – | – | – | 1.994 | 3.343 | 2.952 | -54 | -1.560 | 1.582 | 2.881 | -12.446 | 1.794 | -4.811 | -7.657 | -369 | 2.425 | 3.832 | 639 | -1.097 | -3.506 | -2.656 | 5.421 | -99 | -1.127 | 15.753 | 8.162 | 10.776 | -2.740 | 31.950 |
LTM = letzte zwölf Monate (Summe der jüngsten vier Quartale).
Datenstand: 14. August 2026 · Quelle: Fundamentaldaten & SEC-Berichte (Geschäfts- und Quartalsberichte, 10-K/10-Q)
Hinweis: reine Faktenanalyse, keine Anlageberatung und keine Aufforderung zum Kauf oder Verkauf. Angaben ohne Gewähr.